Valneva SE (NASDAQ:VALN) Q2 2023 Earnings Conference Call September 21, 2023 9:00 AM ET
Company Participants
Joshua Drumm - VP, IR
Thomas Lingelbach - CEO
Peter Buhler - CFO
Conference Call Participants
Maury Raycroft - Jefferies
Samir Devani - Rx Securities
Simon Scholes - First Berlin
Damien Choplain - Oddo BHF
Evan Wang - Guggenheim Securities
Suzanne Van Voorthuizen - VLK
Max Herrmann - Stifel
Operator
Good day, and thank you for standing by. Welcome to the Valneva Half Year 2023 Financial Results Call and Webcast. [Operator Instructions] Please note that today's conference is being recorded.
I would now like to turn the conference over to your speaker, Joshua Drumm, VP, Global Investor Relations. Please go ahead, sir.
Joshua Drumm
Thank you, [Vatia]. Hello and thank you for joining us to discuss Valneva's first half 2023 results and corporate update. It's my pleasure to welcome you today. In addition to our press release and analyst presentation, you can find our consolidated financial results for the six months ended June 30, 2023, which were published earlier today, available within the Financial Reports section on our Investor website.
As always, I'm joined today by Valneva's CEO, Thomas Lingelbach; and CFO, Peter Buhler, who will provide an overview and update of our business, as well as our key financial results for the first half of the year. There will be an analyst Q&A session at the conclusion of the prepared remarks.
Before we begin, I'd like to remind listeners that during this presentation, we'll be making forward-looking statements, which are subject to certain risks and uncertainties that could cause the actual results to differ materially from those expressed or implied by these forward-looking statements. You can find additional information about these risks and uncertainties in our periodic filings with the Securities and Exchange Commission and with the French Market Authority, which are listed on our company website. Please note that today's presentation includes information provided as of today, September 21, 2023, and Valneva undertakes no obligation to revise or update forward-looking statements except as required by applicable securities laws.
With that, it's my pleasure to introduce Thomas to begin today's presentation.
Thomas Lingelbach
Thank you so much, Josh. A very good day everyone. Pleasure for me to report our half year one achievements.
When we look at R&D, we made substantial progress towards the potential FDA approval of the world's first chikungunya vaccine. We have online now the Cohort 1 of the Phase 3 VALOR study completing its first tick season, and the Cohort 2 is currently enrolling, and I will provide more details around that. We decided to reinitiate our Zika vaccine development with an expected clinical trial start early next year. Again, I will provide more details around this.